Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 2/20 | 0.63 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.60 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL397760 | 1.00 | HTR2A (0.63) | HTR2ACYP1A2TAAR1 | |
| SCHEMBL2560760 | 0.83 | HTR2A (0.54) | HTR2ATAAR1 | |
| SCHEMBL5267699 | 0.83 | HTR2A (0.54) | HTR2A | |
| SCHEMBL27133821 | 0.83 | TAAR1 (0.57) | HTR2ATAAR1 | |
| SCHEMBL5461762 | 0.82 | HTR2A (0.65) | HTR2ATAAR1 | |
| SCHEMBL5461766 | 0.82 | HTR2A (0.65) | HTR2ATAAR1 | |
| SCHEMBL5305449 | 0.81 | HTR2A (0.61) | HTR2ACYP1A2TAAR1 | |
| SCHEMBL5305443 | 0.81 | HTR2A (0.61) | HTR2ACYP1A2TAAR1 | |
| SCHEMBL2560674 | 0.81 | HTR2A (0.53) | HTR2ATAAR1 | |
| SCHEMBL2564900 | 0.81 | HTR2A (0.53) | HTR2ACYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 54 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8101661-B2 | Polar hydrophilic prodrugs and non-standard amino acid conjugates of amphetamine and other stimulants and processes for making and using the same | KEMPHARM, INC. (US) | 2012-01-24 | — | — | US | claimed |
| US-20100292336-A1 | Polar Hydrophilic Prodrugs and Non-Standard Amino Acid Conjugates of Amphetamine and Other Stimulants and Processes for Making and Using the Same | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-11-18 | — | — | US | claimed |
| US-12599578-B2 | Compositions comprising enzyme-cleavable prodrugs and controlled release nafamostat and methods of use thereof | Ensysce Biosciences Inc. (US) | 2026-04-14 | — | — | US | disclosed |
| EP-4720030-A1 | ASYMMETRIC PHENYLALKYLAMINES | Alexander Shulgin Research Institute, Inc. (US) | 2026-04-08 | — | — | EP | disclosed |
| EP-4673127-A1 | DEUTERATED AND FLUORINATED EMPATHOGENS | Alexander Shulgin Research Institute, Inc. (US) | 2026-01-07 | — | — | EP | disclosed |
| EP-4673430-A2 | PHENYLALKYLAMINE PRODRUGS | Alexander Shulgin Research Institute, Inc. (US) | 2026-01-07 | — | — | EP | disclosed |
| US-20250388529-A1 | N-Substituted Phenylalkylamines and Their Use as Therapeutic Agents | ALEXANDER SHULGIN RES INSTITUTE INC (US) | 2025-12-25 | — | — | US | disclosed |
| US-12465578-B2 | Substituted alpha-ethyl phenylalkylamines | ALEXANDER SHULGIN RESEARCH INSTITUTE, INC. (US) | 2025-11-11 | — | — | US | disclosed |
| US-20250248969-A1 | COMBINATIONS OF MONOAMINE OXIDASE INHIBITORS AND SEROTONIN RECEPTOR AGONISTS AND THEIR THERAPEUTIC USE | REMEDI INC (US) | 2025-08-07 | — | — | US | disclosed |
| US-20250205198-A1 | METHODS FOR DELIVERY OF PSYCHEDELIC MEDICATIONS BY INHALATION AND SYSTEMS FOR PERFORMING THE METHODS | CYBIN IRL LIMITED (IE) | 2025-06-26 | — | — | US | disclosed |
| US-20250195471-A1 | ASYMMETRIC ALLYL TRYPTAMINES | ALEXANDER SHULGIN RES INSTITUTE INC (US) | 2025-06-19 | — | — | US | disclosed |
| EP-2560486-A1 | COMPOSITIONS COMPRISING ENZYME-CLEAVABLE AMPHETAMINE PRODRUGS AND INHIBITORS THEREOF | Signature Therapeutics, Inc. (US) | 2013-02-27 | — | — | EP | disclosed |
| US-20120232066-A1 | COMPOSITIONS FOR REDUCING RISK OF ADVERSE EVENTS CAUSED BY DRUG-DRUG INTERACTIONS | SIGNATURE THERAPEUTICS, INC. | 2012-09-13 | — | — | US | disclosed |
| WO-2012122412-A2 | COMPOSITIONS FOR REDUCING RISK OF ADVERSE EVENTS CAUSED BY DRUG-DRUG INTERACTIONS | SIGNATURE THERAPEUTICS, INC. (US) | 2012-09-13 | — | — | WO | disclosed |
| US-8101661-B2 | Polar hydrophilic prodrugs and non-standard amino acid conjugates of amphetamine and other stimulants and processes for making and using the same | KEMPHARM, INC. (US) | 2012-01-24 | — | — | US | disclosed |
| WO-2011133348-A1 | COMPOSITIONS COMPRISING ENZYME-CLEAVABLE AMPHETAMINE PRODRUGS AND INHIBITORS THEREOF | PHARMACOFORE, INC. (US) | 2011-10-27 | — | — | WO | disclosed |
| WO-2011133347-A1 | COMPOSITIONS COMPRISING TRYPSIN-CLEAVABLE AMPHETAMINE PRODRUGS AND INHIBITORS THEREOF | PHARMACOFORE, INC. (US) | 2011-10-27 | — | — | WO | disclosed |
| US-20100292336-A1 | Polar Hydrophilic Prodrugs and Non-Standard Amino Acid Conjugates of Amphetamine and Other Stimulants and Processes for Making and Using the Same | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-11-18 | — | — | US | disclosed |
| WO-2007016190-A2 | ANTIPARKINSONIAN ACTION OF PHENYLISOPROPYLAMINES | DUKE UNIVERSITY (US) | 2007-02-08 | — | — | WO | disclosed |
| US-20070027208-A1 | Antiparkinsonian Action of Phenylisopropylamines | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2007-02-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250388529-A1 | N-Substituted Phenylalkylamines and Their Use as Therapeutic Agents | CNR2, CNR1, HCN3 | HTR2A 25/4885CYP1A2 623/4885TAAR1 24/4885 |
| US-20070027208-A1 | Antiparkinsonian Action of Phenylisopropylamines | PNMT, SNCA, COMT | HTR2A 18/4885CYP1A2 786/4885TAAR1 1075/4885 |
| US-20250195471-A1 | ASYMMETRIC ALLYL TRYPTAMINES | TPH2, TPH1, HTR2A | HTR2A 3/4885CYP1A2 351/4885TAAR1 37/4885 |
| US-12465578-B2 | Substituted alpha-ethyl phenylalkylamines | PNMT, SLC18A2, SLC1A2 | HTR2A 4/4885CYP1A2 371/4885TAAR1 48/4885 |
| US-20100292336-A1 | Polar Hydrophilic Prodrugs and Non-Standard Amino Acid Conjugates of Amphetamine and Other Stimulants and Processes for Making and Using the Same | SLC18A2, SLC6A19, SLC6A2 | HTR2A 83/4885CYP1A2 197/4885TAAR1 72/4885 |
| US-20120232066-A1 | COMPOSITIONS FOR REDUCING RISK OF ADVERSE EVENTS CAUSED BY DRUG-DRUG INTERACTIONS | CYP2C19, CYP3A5, CYP3A4 | HTR2A 823/4885CYP1A2 11/4885TAAR1 1084/4885 |
| US-12599578-B2 | Compositions comprising enzyme-cleavable prodrugs and controlled release nafamostat and methods of use thereof | OPRK1, OPRL1, OPRM1 | HTR2A 2491/4885CYP1A2 162/4885TAAR1 543/4885 |
| US-20250205198-A1 | METHODS FOR DELIVERY OF PSYCHEDELIC MEDICATIONS BY INHALATION AND SYSTEMS FOR PERFORMING THE METHODS | HTR2C, PNMT, HTR2A | HTR2A 3/4885CYP1A2 108/4885TAAR1 24/4885 |
| US-20250248969-A1 | COMBINATIONS OF MONOAMINE OXIDASE INHIBITORS AND SEROTONIN RECEPTOR AGONISTS AND THEIR THERAPEUTIC USE | MAOA, MAOB, HTR1A | HTR2A 9/4885CYP1A2 63/4885TAAR1 52/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.